Acceptance and Efficacy of Live Supervision

Mental Disorders Clinical Trial

Official title:

Live Supervision Put to Test - Studies of Acceptance and Efficacy of Computer-assisted Live Supervision

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01510080
• Other study ID #: WECK-012
• Status: Completed
• Phase: N/A
• First received: December 12, 2011
• Last updated: January 19, 2015
• Start date: January 2012
• Est. completion date: August 2014

Study information

• Verified date: January 2015
• Source: Goethe University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

In order to meet an existing lack of empirical studies in the field of cognitive behavioral therapy supervision, the present randomized controlled trial is aimed at comparing two different types of supervision. This study compares computer-assisted live supervision and delayed video-based supervision regarding efficacy and acceptance among therapists, patients and supervisors. The efficacy of supervision is defined on different levels such as change of psychotherapeutic competence, nondisclosure, self-efficacy, self-awareness of the supervisee as well as therapeutic alliance, supervisory alliance and therapy outcome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Supervisees

Inclusion Criteria:

• Having successfully completed the interim audit

• Having started to treat ambulant patients under supervision

Exclusion Criteria:

Patients

Inclusion Criteria:

• Meeting ICD 10 criteria for a mental disorder

• Informed consent

Exclusion Criteria:

• Currently in psychotherapy

• Suicidal tendency

• Clinical diagnosis of alcohol or drug addiction, acute schizophrenia, schizoaffective disorder or bipolar disorder

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Mental Disorders
• Psychotic Disorders

Intervention

Behavioral:
• Computer-assisted live supervision
8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
• Delayed video-based supervision
12 video-based sessions (each 50 minutes) during treatment of 2 patients

Locations

Country	Name	City	State
Germany	Department of Clinical Psychology and Psychotherapy of the Wolfgang Goethe University	Frankfurt	Hessen

Sponsors (2)

Lead Sponsor	Collaborator
Goethe University	Central Institute of Mental Health, Mannheim

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Supervisory Questionnaire (SQ)	self-report measure that assesses nondisclosure of the supervisee during supervision	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Primary	Supervisee Levels Questionnaire (SLQ-R)	self-report measure that assesses self awareness, motivation and dependency- autonomy of supervisees	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Primary	Counseling Self-Estimate Inventory (COSE)	self-report measure that assesses self efficacy of the supervisee	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Primary	Fragebogen zur Psychotherapie-Supervision Kurzform (FSPT-K)	self-report measure that assesses level of development and supervision needs of the therapist	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Helping Alliance Questionnaire (HAQ)	self-report measure that assesses the therapeutic alliance	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Supervisory Working Alliance Inventory (SWAI)	self-report measure that assesses the supervisory relationship	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Beck-Depression Inventory II (BDI-II)	self-report measure that assesses depressive symptoms	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Beck Anxiety Inventory II (BAI)	self-report measure that asessses anxiety symptoms	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Brief Symptom Inventory (BSI)	self-report measure that assesses aspects of general psychopathology	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Health-related quality of life (SF-12)	self-report measure that assesses the health-related quality of life	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Client Satisfaction Questionnaire (CSQ8)	self-report measure that assesses satisfaction with therapy	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Stundenbogen zur Supervisionsbeurteilung (STEP SV)	self-report measure that assesses satisfaction with supervision	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No
Secondary	Cognitive Therapy Scale (CTS)	clinician-rated measure that assesses psychotherapeutic competencies	participants will be followed for the duration of psychotherapy, an expected average of 30 weeks	No